Carol J Farhangfar
Overview
Explore the profile of Carol J Farhangfar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
149
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El-Deiry W, Bresson C, Wunder F, Carneiro B, Dizon D, Warner J, et al.
Oncotarget
. 2025 Mar;
16:140-162.
PMID: 40073368
The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed...
2.
Farhangfar C, Mileham K, Tan A
JCO Oncol Pract
. 2024 Nov;
20(11):1452-1459.
PMID: 39531850
No abstract available.
3.
Ivanina Foureau A, Foureau D, McHale C, Guo F, Farhangfar C, Mileham K
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001537
Phosphosidesterases (PDEs) are key regulators of cyclic nucleotide signaling, controlling many hallmarks of cancer and playing a role in resistance to chemotherapy in non-small-cell lung cancer (NSCLC). We evaluated the...
4.
Mileham K, Farhangfar C
JCO Oncol Pract
. 2023 Aug;
19(9):694-696.
PMID: 37607326
No abstract available.
5.
Ivanina Foureau A, Sha W, Foureau D, Symanowski J, Farhangfar C, Mileham K
Transl Lung Cancer Res
. 2023 Jan;
11(12):2464-2476.
PMID: 36636422
Background: Metabolomics studies to date have described widespread metabolic reprogramming events during the development of non-squamous non-small cell lung cancer (NSCLC). Extending far beyond the Warburg effect, not only is...
6.
Jagosky M, Anderson C, Symanowski J, Steuerwald N, Farhangfar C, Baldrige E, et al.
Cancer Med
. 2022 Dec;
12(6):7029-7038.
PMID: 36464833
Purpose: Patients with unresectable dedifferentiated liposarcoma (DDLPS) have poor overall outcomes. Few genomic alterations have been identified with limited therapeutic options. Experimental Design: Patients treated at Levine Cancer Institute with...
7.
Farhangfar C, Scarola G, Morris V, Farhangfar F, Dumas K, Symanowski J, et al.
JCO Clin Cancer Inform
. 2022 Jul;
6:e2200011.
PMID: 35839431
Purpose: Clinical trials of novel and targeted agents increasingly require biomarkers for eligibility. Precision oncology continues to evolve, but challenges hamper broad use of molecular profiling (MP) that could increase...
8.
Livingston M, Jagosky M, Robinson M, Ahrens W, Benbow J, Farhangfar C, et al.
Clin Cancer Res
. 2021 Sep;
27(23):6424-6431.
PMID: 34475102
Purpose: Doxorubicin is standard therapy for advanced soft-tissue sarcoma (STS) with minimal improvement in efficacy and increased toxicity with addition of other cytotoxic agents. Pembrolizumab monotherapy has demonstrated modest activity...
9.
Arango N, Brusco L, Mills Shaw K, Chen K, Eterovic A, Holla V, et al.
Oncotarget
. 2019 Sep;
10(50):5254.
PMID: 31497255
[This corrects the article DOI: 10.18632/oncotarget.16018.].
10.
Arango N, Brusco L, Mills Shaw K, Chen K, Eterovic A, Holla V, et al.
Oncotarget
. 2017 Apr;
8(26):41806-41814.
PMID: 28415679
Purpose: Molecular profiling performed in the research setting usually does not benefit the patients that donate their tissues. Through a prospective protocol, we sought to determine the feasibility and utility...